To the Editor.—
Sulindac is a nonsteroidal anti-inflammatory agent used commonly in the treatment of rheumatoid arthritis. The side effects, estimated to be about 25%,1 usually involve the gastrointestinal system and CNS. We describe a patient who experienced gynecomastia after sulindac therapy, a previously unreported complication of this drug.
Report of a Case.—
A 63-year-old man had a condition diagnosed as rheumatoid arthritis. He had morning stiffness and progressive symmetrical polyarthritis of his shoulders, wrists, hands, knees, and ankles. The complete blood cell (CBC) count was normal, sedimentation rate was 46 mm/hr, rheumatoid factor titer was 1:1,725, antinuclear antibody was 1:80, and roentgenograms of both hands were consistent with the diagnosis. He had a poor response to aspirin and, while he was receiving aurothioglucose, an exfoliative dermatitis developed. Hence, he started receiving sulindac, 200 mg twice daily. After four months, he noticed occasionally painful left breast enlargement. There was
Kapoor A. Reversible Gynecomastia Associated With Sulindac Therapy. JAMA. 1983;250(17):2284–2285. doi:10.1001/jama.1983.03340170022012
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: